Sales of Regeneron's Eylea eye drug slow, shares dropBy Esha Dey and Bill Berkrot (Reuters) - The explosive growth in the sales of Regeneron Pharmaceuticals Inc's Eylea eye drug slowed in the second quarter as existing patients moved to less-frequent dosing. Shares of Regeneron fell 6.1 percent on Tuesday even though the company said it plans to file for wider use of the injectable drug later this year, following positive new trial data. Analysts, who were already expecting positive data from the trials targeted at diabetic macular edema (DME), focused on Eylea's slowing sales growth. ...
Source: Sales of Regeneron's Eylea eye drug slow, shares drop (http://news.yahoo.com/regenerons-eylea-improves-vision-diabetic-eye-condition-063128365.html)